文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛消化、代谢与肾脏急症

脓毒症表型与慢性病患者个体化液体治疗

[Sepsis phenotypes and individualized fluid therapy in patients with chronic diseases].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2026-01-01
一句话结论脓毒症表型分类可指导慢性病患者的个体化液体治疗,但现有证据尚缺高质量前瞻性试验验证。

该综述指出脓毒症是感染引发失调宿主反应导致的临床综合征,慢性病患者因器官储备受损和免疫失衡更易发病且死亡风险更高。液体复苏仍是脓毒症管理基石,但「一刀切」策略不适合慢性病患者。基于机器学习从单维或多维临床指标及单组学或多组学衍生的脓毒症表型与液体反应性和患者结局密切相关,慢性心衰、慢性肾病、COPD或肝硬化患者不同表型对液体策略反应不同。表型导向液体管理前景可观,但存在表型重叠、动态表型漂移及缺乏高质量前瞻性临床试验等挑战。

要点

  • 慢性病患者因器官储备受损和免疫失衡,对脓毒症更易感且死亡风险更高。
  • 液体复苏仍是脓毒症管理基石,但「一刀切」策略不适合慢性病患者。
  • 基于机器学习从临床指标或组学衍生的脓毒症表型与液体反应性和患者结局密切相关。
  • 慢性心衰、慢性肾病、COPD或肝硬化患者中,不同表型对液体策略反应不同。
  • 表型导向液体管理面临表型重叠、动态表型漂移及缺乏高质量前瞻性临床试验等挑战。

适用人群与场景

  • 脓毒症患者,尤其是合并慢性疾病(如慢性心力衰竭、慢性肾脏病、慢性阻塞性肺疾病或肝硬化)的患者。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文提及液体复苏是脓毒症管理的基石,并提倡基于表型的个体化液体治疗,但未给出具体药物、剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 综述指出,基于单维或多维临床指标以及单组学或多组学方法衍生的脓毒症表型与液体反应性和患者结局密切相关;在慢性心衰、慢性肾病、COPD或肝硬化患者中,不同表型对液体策略的反应不同。

证据类型、等级与局限

  • 证据类型为综述;原文未给出证据等级或推荐强度;局限性包括表型重叠、动态表型漂移以及缺乏高质量前瞻性临床试验。

对床旁实践的改变

  • 提示对合并慢性病的脓毒症患者,不应采用「一刀切」的液体复苏策略,可考虑基于表型分类指导个体化液体治疗,但需注意现有证据尚未经高质量前瞻性试验验证。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

Sepsis is a clinical syndrome caused by a dysregulated host response to infection, often resulting in life-threatening organ dysfunction. Patients with chronic diseases are more susceptible to sepsis and have a higher risk of mortality due to impaired organ reserve and immune imbalance. Fluid resuscitation remains a cornerstone of sepsis management. However, a "one-size-fits-all" approach may not be suitable for patients with chronic diseases. In recent years, with the development of machine learning, researchers have proposed phenotype-based classification to identify the heterogeneity of sepsis and guide individualized fluid therapy. Evidence indicates that sepsis phenotypes derived from single or multidimensional clinical indicators, as well as single-omics or multi-omics approaches, are closely associated with fluid responsiveness and patient outcomes. Notably, in patients with chronic heart failure, chronic kidney disease, chronic obstructive pulmonary disease (COPD), or cirrhosis, different phenotypes show distinct responses to fluid strategies. Although existing findings suggest that phenotype-directed fluid management shows significant promise, several major challenges persist, such as phenotype overlap, dynamic phenotypic shifts, and the lack of high-quality prospective clinical trials. Future research should integrate large-scale, multimodal data to establish dynamic and reproducible phenotyping systems, and validate phenotype-specific fluid strategies through clinical trials, thereby advancing sepsis treatment from empirical management toward precision medicine.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Yu R, Shi N, Xie J, et al. [Sepsis phenotypes and individualized fluid therapy in patients with chronic diseases]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 42427335. doi:10.3760/cma.j.cn121430-20251111-00546

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。